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Abstract
Background: Our objective was to compare
111In- or
64Cu-DOTA-trastuzumab Fab fragments for imaging small or
large s.c. tumor xenografts in athymic mice that display a wide range of human epidermal growth factor receptor-
2 (HER2) expression using microSPECT/CT or microPET/CT.
Methods: Trastuzumab Fab were labeled with
111In or
64Cu by conjugation to 1,4,7,10-tetraazacyclododecane N, N’,
N’’,N ’’’-tetraacetic acid (DOTA). The purity of
111In- and
64Cu-DOTA-trastuzumab Fab was measured by SDS-PAGE
and HPLC. HER2 binding affinity was determined in saturation radioligand binding assays using SKBR-3 cells (1.3 ×
10
6 HER2/cell). MicroSPECT/CT and microPET/CT were performed in athymic mice bearing s.c. BT-20 and MDA-MB-
231 xenografts with low (0.5 to 1.6 × 10
5 receptors/cell), MDA-MB-361 tumors with intermediate (5.1 × 10
5
receptors/cell) or SKOV-3 xenografts with high HER2 expression (1.2 × 10
6 receptors/cell) at 24 h p.i. of 70 MBq (10
μg) of
111In-DOTA-trastuzumab Fab or 22 MBq (10 μg) of
64Cu-DOTA-trastuzumab Fab or irrelevant
111In- or
64Cu-
DOTA-rituximab Fab. Tumor and normal tissue uptake were quantified in biodistribution studies.
Results:
111In- and
64Cu-DOTA-trastuzumab were > 98% radiochemically pure and bound HER2 with high affinity
(Kd = 20.4 ± 2.5 nM and 40.8 ± 3.5 nM, respectively). MDA-MB-361 and SKOV-3 tumors were most clearly imaged
using
111In- and
64Cu-DOTA-trastuzumab Fab. Significantly higher tumor/blood (T/B) ratios were found for
111In-
DOTA-trastuzumab Fab than
111In-DOTA-rituximab Fab for BT-20, MDA-MB-231 and MDA-MB-361 xenografts, and
there was a direct association between T/B ratios and HER2 expression. In contrast, tumor uptake of
64Cu-DOTA-
trastuzumab Fab was significantly higher than
64Cu-DOTA-rituximab Fab in MDA-MB-361 tumors but no direct
association with HER2 expression was found. Both
111In- and
64Cu-DOTA-trastuzumab Fab imaged small (5 to 10
mm) or larger (10 to 15 mm) MDA-MB-361 tumors. Higher blood, liver, and spleen radioactivity were observed for
64Cu-DOTA-trastuzumab Fab than
111In-DOTA-trastuzumab Fab.
Conclusions: We conclude that
111In-DOTA-trastuzumab Fab was more specific than
64Cu-DOTA-trastuzumab Fab
for imaging HER2-positive tumors, especially those with low receptor density. This was due to higher levels of
circulating radioactivity for
64Cu-DOTA-trastuzumab Fab which disrupted the relationship between HER2 density
and T/B ratios. Use of alternative chelators that more stably bind
64Cu may improve the association between T/B
ratios and HER2 density for
64Cu-labeled trastuzumab Fab.
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The human epidermal growth factor receptor-2 (HER2) is
overexpressed in 20% to 25% of breast cancers (BC) and is
the target for treatment with trastuzumab (Herceptin), a
humanized IgG1 monoclonal antibody (mAb) [1,2]. HER2
amplification is normally assessed ex vivo in a primary
tumor biopsy by immunohistochemical (IHC) staining for
HER2 protein or by fluoresecence in situ hybridization to
detect increased HER2 gene copy number [3]. However,
discordance in HER2 expression between primary and
metastatic BC has been found in 20% to 30% of cases [4,5]
and thus, it would be useful to have an imaging technique
to assess HER2 phenotype in situ in BC lesions. Several
investigators have shown that HER2 expression can be
imaged in human BC xenografts in athymic mice by single
photon emission computed tomography (SPECT) using
trastuzumab or its Fab fragments labeled with
111In or
99
mTc [6-9]. These studies have been extended to imaging
HER2-positive BC in patients using
111In-labeled trastuzu-
mab IgG [2,10]. More recently, positron-emission tomo-
graphy (PET) using trastuzumab labeled with
89Zr has
shown promise for imaging HER2 expression in tumor
xenograft mouse models and in patients with metastatic
BC [11,12]. Imaging also offers an opportunity to detect
response to HER2-targeted therapies in BC [13]. We pre-
viously reported that SPECT with
111In-labeled pertuzu-
mab (anti-HER2) detected early response to treatment
with trastuzumab (Herceptin) in athymic mice bearing s.c.
MDA-MB-361 BC xenografts [14]. Smith-Jones et al.
demonstrated that PET with
68Ga-labeled trastuzumab F
(ab’)2 fragments identified response of HER2-positive BT-
474 human BC tumors in mice to treatment with heat
shock protein (Hsp90) inhibitors [15].
PET offers several potential advantages compared to
SPECT for imaging tumors because it has higher intrinsic
sensitivity, is more easily quantified, and in some
instances offers higher spatial resolution. Despite these
apparent benefits, few studies have reported a compari-
son of PET and SPECT for imaging HER2-positive
tumors using the same agent labeled with a single
photon-emitter or positron-emitter. Dijkers et al. com-
pared
89Zr- and
111In-labeled trastuzumab in mice bear-
ing s.c. SK-OV-3 human ovarian cancer xenografts and
reported no significant differences in tumor and normal
tissue uptake [12]. MicroPET with
89Zr-labeled trastuzu-
mab visualized these tumors, but the corresponding
microSPECT images with
111In-labeled trastuzumab were
not presented.
In this study, we compared microSPECT/CT and
microPET/CT for imaging s.c. human tumor xenografts
expressing a wide range of HER2 density in athymic
mice using trastuzumab Fab fragments modified with
1,4,7,10-tetraazacyclododecane N, N’,N ″,N ’″-tetraacetic
acid (DOTA) for complexing
111In or
64Cu.
64Cu decays
with a half-life of 12.7 h by positron emission [Eb
+ =
0.65 MeV (17.4%)], b
- emission [Eb = 0.58 MeV (39%)]
and electron capture (43.6%).
111In decays by electron
capture with a half-life of 2.8 days emitting Auger elec-
trons and two g-photons [Eg = 171 keV (90%) and 245
keV (94%)]. DOTA was selected as a chelator because
both
111In and
64Cu form thermodynamically stable
complexes with DOTA (Kd =1 0
24 and 10
23 M
-1, respec-
tively) [16,17].
64Cu complexed to DOTA and linked to
mAbs and peptides has been widely studied for PET
imaging of tumors [15,18-23]. Fab fragments were
selected for these studies because their pharmacokinetics
of tumor uptake and elimination from the blood and
normal tissues is compatible with the half-lives of
64Cu
and
111In [24].
Materials and methods
Preparation of Fab fragments
Trastuzumab (Herceptin) and rituximab (anti-CD20;
Rituxan) are humanized IgG1 mAbs and were obtained
from Roche Pharmaceuticals Ltd. (Mississauga, ON,
Canada). Fab fragments were prepared by digestion with
immobilized papain (Pierce Chemical Co., Rockford, IL,
USA) and purified as reported [7,25]. Fab purity was
assessed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) on a 4% to 20% Tris HCl gra-
dient mini-gel (BioRad, Mississauga, ON, Canada) and by
size-exclusion high performance liquid chromatography
(HPLC). For SDS-PAGE, Fab (10 μg) were electrophoresed
under non-reducing and reducing [dithiothreitol (DTT)]
conditions. The gel was stained with Coomassie R-250
brilliant blue (Bio-Rad). Size-exclusion HPLC was per-
formed on a BioSep SEC-2000 column (Phenomenex,
Torrance, CA, USA) eluted with 100 mM NaH2PO4 buffer
(pH 7.0) at a flow rate of 0.8 mL/min in line with a diode
array detector (PerkinElmer, Wellesley, MA, USA) moni-
toring at 280 nm. Fab fragments were concentrated and
buffer-exchanged into 50 mM NaHCO3 buffer (pH 7.5)
on an Amicon Ultracel 30 K device (Mr cut-off = 30 kDa;
Millipore Corp., Billerica, MA, USA). Trace metals were
removed from all buffers using Chelex-100 cation-
exchange resin (BioRad). The final Fab fragments concen-
tration was measured spectrophotometrically [E280 nm =
1.45 (mg/mL)
-1 cm
-1] [7] and was adjusted to 5 mg/mL
with 50 mM NaHCO3 buffer, pH 7.5.
DOTA conjugation and radiolabeling of Fab fragments
Trastuzumab or rituximab Fab fragments were modified
with DOTA for complexing
111In or
64Cu by reaction of
1.5 mg of Fab in 300 μLo fN a H C O 3 buffer (pH 7.5)
with a 60- or 90-fold excess, respectively, of the N-
hydroxysuccinimidyl ester of 1,4,7,10-tetraazacyclodode-
cane tetraacetic acid (NHS-DOTA; Macrocyclics, Dallas,
TX, USA). The conjugation reaction was performed at
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Page 2 of 114°C for 18 h. DOTA-conjugated Fab were purified from
excess DOTA by transferring to an Amicon Ultracel 30
K device, diluting to 12.0 mL with 1 M CH3COONH4
buffer, pH 6.0 and centrifuging at 4,000 × g for 15 min.
This purification step was repeated six times. Finally,
purified DOTA-Fab were recovered and the concentra-
tion determined spectrophotometrically [E280 nm =1 . 4 5
(mg/mL)
-1 cm
-1]. The final concentration was adjusted
to 5 mg/mL with 1 M CH3COONH4 buffer, pH 6.0.
Radiolabeling was performed by incubating 50 μgo f
DOTA-Fab in 10 μLo fC H 3COONH4 buffer, pH 6.0 with
360 MBq of
111InCl3 (> 7 GBq/mL; MDS-Nordion,
Kanata, ON, Canada) or 216 MBq of
64CuCl2 (> 4 GBq/
mL; MDS-Nordion) for 3 h at 46°C.
111In- or
64Cu-labeled
DOTA-Fab were purified on an Amicon Ultracel 30 K
device. The final radiochemical purity was measured by
instant thin layer-silica gel chromatography (ITLC-SG;
Pall Life Sciences, Ann Arbor, MI, USA) developed in 100
mM sodium citrate, pH 5.0 or by size-exclusion HPLC
using a flow-through radioactivity detector (FSA; PerkinEl-
mer). The Rf values for
111In- or
64Cu-DOTA-Fab on
ITLC were 0.0 and those for
111In- or
64Cu-DOTA or free
radionuclides were 1.0. The DOTA substitution level of
the Fab fragments (chelators/molecule) was measured by
labeling a 10 μL aliquot of the unpurified conjugation
reaction with
111In, then determining the proportion of
111In-DOTA-Fab vs.f r e e
111In-DOTA by ITLC-SG and
multiplying this fraction by the molar ratio used in the
reaction [26].
HER2 binding affinity of
111In- and
64Cu-DOTA-
trastuzumab Fab
The HER2 binding affinity of
111In- and
64Cu-DOTA-
trastuzumab Fab was determined by direct (saturation)
radioligand binding assays using SKBR-3 human BC
cells (1.3 × 10
6 HER2/cell) [9]. Briefly, increasing con-
centrations (0 to 600 nmol/L) of
111In- or
64Cu-DOTA-
trastuzumab Fab were incubated with 1 × 10
5 cells in
24-well plates at 4°C for 3 h. Unbound radioactivity was
removed and the dishes were rinsed two times with
phosphate-buffered saline. The cells were dissolved in
100 mM NaOH, recovered, and the total cell-bound
radioactivity (TB) was measured in a g-counter (Perki-
nElmer Wizard 3). The assay was repeated in the pre-
sence of 16 μmol/L of unlabeled trastuzumab IgG to
measure non-specific binding (NSB). Specific binding
(SB; nanomoles per liter) was calculated by subtracting
N S Bf r o mT Ba n dw a sp l o t t e dvs. the concentration of
111In- or
64Cu-DOTA-trastuzumab Fab (nanomoles per
liter) added. The resulting curve was fitted by non-linear
regression to a one-site receptor-binding model by
Prism Ver. 4.0 software (GraphPad, San Diego, CA,
USA). The dissociation constant (Kd) and maximum
number of receptors per cell (Bmax) were calculated and
compared for
111In- and
64Cu-DOTA-trastuzumab Fab.
Tumor and normal tissue distribution studies
The tumor and normal tissue distribution of
111In- or
64Cu-DOTA-trastuzumab Fab were determined at 24-h
post-intravenous (tail vein) injection (p.i.) in athymic mice
with s.c. human tumor xenografts with a wide range of
HER2 density. This time point was selected due to the
short physical half-life of
64Cu (12.7 h) and because high
tumor uptake [> 5 percent injected dose per gram (% i.d./
g)] and tumor/blood (T/B)r a t i o s( >4 : 1 )w e r ep r e v i o u s l y
found for
111In-DTPA-trastuzumab Fab at 24 h p.i. [7].
Tumors were established in female athymic (CD1-nude)
mice by s.c. inoculation of 1 × 10
7 MDA-MB-231, BT-20,
or MDA-MB-361 BC cells expressing 5.4 × 10
4, 1.6 × 10
5,
or 5.1 × 10
5 HER2/cell, respectively, or with SK-OV-3
ovarian cancer cells displaying 1.2 × 10
6 HER2/cell [27]. At
4 to 7 weeks post-inoculation, when tumors were well
established (5 to 15 mm in diameter), groups of mice (n =
4) were injected i.v. (tail vein) with 12 MBq (10 μg) of
111In-DOTA-trastuzumab Fab or 18 MBq (10 μg) of
64Cu-
DOTA-trastuzumab Fab. To determine if tumor uptake
was specific, control groups of mice (n =4 )w i t hM D A -
MB-231, BT-20, or MDA-MB-361 xenografts were injected
i.v. with 12 MBq (10 μg) of irrelevant
111In-DOTA-rituxi-
mab Fab or 18 MBq (10 μg) of
64Cu-DOTA-rituximab Fab.
Mice were euthanized by cervical dislocation under general
anaesthesia. Tumor and normal tissue uptake of radioactiv-
ity was measured in a g-scintillation counter (Wizard 3,
PerkinElmer, Waltham, MA) was expressed as percent
injected dose per gram and as tumor/normal tissue (T/NT)
ratios. The relationship between tumor/blood (T/B) ratios
and HER2 density was examined. The uptake of
111In- or
64Cu-DOTA-trastuzumab Fab fragments in small (5 to 10
mm diameter) vs. larger (10 to 15 mm diameter) tumor
xenografts was compared.
MicroSPECT and microPET imaging
MicroSPECT was performeda t2 4hp . i .o f7 0M B q( 1 0
μg) of
111In-DOTA-trastuzumab Fab or
111In-DOTA-
rituximab Fab in athymic mice with s.c. HER2-positive
tumor xenografts. Anaesthesia was induced and main-
tained by inhalation of 2% isoflurane in O2. MicroSPECT
was performed on a NanoSPECT/CT tomograph (Bioscan,
Washington, DC, USA) equipped with four NaI scintilla-
tion detectors fitted with 1.4-mm multi-pinhole collima-
tors [full-width half-maximum (FWHM) = 1.2 mm]. A
total of 24 projections were acquired in a 256 × 256 matrix
with a minimum of 80,000 counts per projection. Micro-
SPECT image acquisition time was 85 to 120 mins. Micro-
SPECT images were reconstructed using an ordered-
subset expectation maximization (OSEM) algorithm (nine
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Page 3 of 11iterations). Prior to microSPECT imaging, cone-beam CT
images were acquired (180 projections, 1 s/projection, 45
kVp) on the NanoSPECT/CT system. Co-registration of
microSPECT and CT images was performed using Invivo-
Scope software (Bioscan).
MicroPET was performed at 24 h p.i. of 22 MBq (10 μg)
of
64Cu-DOTA-trastuzumab Fab or
64Cu-DOTA-rituxi-
mab Fab on a Focus 220 microPET tomograph (Siemens
Preclinical Solutions, Knoxville, TN, USA). Images were
acquired for 20 mins and reconstructed using OSEM, fol-
lowed by a maximum a posteriori probability reconstruc-
tion algorithm with no correction for attenuation or
partial-volume effects. The FWHM resolution of the
microPET tomograph was 1.6 mm. Immediately after ima-
ging, CT was performed on an eXplore Locus Ultra Precli-
nical CT scanner (GE Healthcare, Mississauga, ON,
Canada) with routine acquisition parameters (80 kVp,
70 mA, and voxel size of 150 × 150 × 150 mm). MicroPET
and CT images were coregistered using Inveon Research
Workplace software (Siemens). All animal studies were
conducted under a protocol (no. 989.9) approved by the
Animal Use Committee at the University Health Network
following Canadian Council on Animal Care guidelines.
Statistical analyses
Statistical significance of comparisons were assessed by
Student’s t test (P < 0.05).
Results
Preparation of
111In and
64Cu-labeled DOTA-Fab
fragments
SDS-PAGE (Figure 1a) and size-exclusion HPLC (Fig-
ure 1b,c) demonstrated that pure (> 98%) Fab frag-
ments of trastuzumab and rituximab were obtained by
digestion of intact IgG1 with immobilized papain using
a previously reported method [7,25]. Reaction of tras-
tuzumab and rituximab Fab with a 60- or 90-fold
excess of NHS-DOTA for 18 h at 4°C resulted in sub-
stitution of 3.7 ± 0.2 and 2.5 ± 0.3 DOTA chelators
per molecule, respectively. The pre-purification label-
ing efficiencies for
111In-DOTA-trastuzumab Fab,
111In-DOTA-rituximab Fab,
64Cu-DOTA-trastuzumab
Fab, and
64Cu-DOTA-rituximab Fab were 75.5 ± 5.4%,
76.8 ± 1.5%, 65.9 ± 4.9%, and 67.9 ± 5.7%, respectively.
Following purification, the radiochemical purity was >
98% for all radioimmunoconjugates by ITLC (not
shown) and size-exclusion HPLC (Figure 1b,c). The
specific activities of
111In- and
64Cu-DOTA-trastuzu-
mab Fab fragments used in microSPECT and micro-
PET and biodistribution studies were 3.6 to 4.9 MBq/
μga n d1 . 3t o4 . 7M B q / μg, respectively. The specific
activities of
111In- and
64Cu-DOTA-rituximab Fab
were 1.3 to 5.8 and 1.9 to 2.8 MBq/μg.
HER2 binding affinity of
111In- and
64Cu-DOTA-
trastuzumab Fab
Direct (saturation) radioligand binding assays showed
that
111In- and
64Cu-DOTA-trastuzumab Fab bound
specifically to HER2 on SKBR-3 cells (Figure 2a,b). The
Kd values for
111In- and
64Cu-DOTA-trastuzumab Fab
were 20.4 ± 2.5 nM and 40.8 ± 3.5 nM (P <0 . 0 1 ) ,
respectively. These values were similar to the Kd for
111In-DTPA-trastuzumab Fab binding to SKBR-3 cells
previously reported by our group (Kd = 48 nM) [25].
There was no specific binding of
111In-DOTA-rituximab
to SKBR-3 cells (not shown). The Bmax values for
111In-
and
64Cu-DOTA-trastuzumab Fab on SKBR-3 cells were
1.4 ± 0.1 × 10
6 receptors/cell and 2.3 ± 0.1 × 10
6 recep-
tors/cell, respectively (P < 0.001).
Tumor and normal tissue distribution studies
The tumor and normal tissue uptake of
111In- and
64Cu-
DOTA-trastuzumab Fab at 24 h p.i. in athymic mice
bearing s.c. MDA-MB-361 human BC xenografts (5.1 ×
10
5 HER2/cell) are shown in Table 1. Blood levels were
threefold significantly higher for
64Cu- than
111In-
DOTA-trastuzumab Fab (1.40 ± 0.16% vs. 0.42 ± 0.08%
i.d./g; P < 0.0001). Similarly, liver uptake was threefold
significantly greater for
64Cu- than
111In-DOTA-trastu-
zumab Fab (8.52 ± 0.81% vs. 3.13 ± 0.15% i.d./g; P <
0.0001). Radioactivity concentrations were higher in
heart, lungs, stomach, intestines, and spleen for
64Cu-
than
111In-DOTA-trastuzumab Fab (Table 1). However,
kidney uptake was not significantly different between
64Cu- and
111In-DOTA-trastuzumab Fab (57.00 ± 7.09%
vs. 62.85 ± 6.45% i.d./g; P = 0.268). There was no signifi-
cant difference in tumor accumulation for
111In- and
64Cu-DOTA-trastuzumab Fab (4.00 ± 0.90% vs.5 . 0 0±
1.2% i.d./g; P = 0.228). Due to the higher blood and
liver radioactivity, the T/B and tumor/liver (T/L)r a t i o s
were three- and twofold significantly lower, respectively
for
64Cu- than
111In-DOTA-trastuzumab Fab (3.56 ±
0.62 vs. 9.73 ± 2.46; P = 0.003 and 0.59 ± 0.16 vs. 1.27 ±
0.26 vs.; P = 0.004, respectively; Table 2). T/NT ratios
for
64Cu-DOTA-trastuzumab Fab were significantly
lower than
111In-DOTA-trastuzumab Fab for all tissues
except kidneys and muscle (Table 2). There was no sig-
nificant difference in the uptake of
111In- or
64Cu-
DOTA-trastuzumab Fab in small (5 to 10 mm diameter)
vs. larger (10 to 15 mm) MDA-MB-361 tumor xeno-
grafts (4.00 ± 0.91% vs. 6.12 ± 0.84% i.d./g; P = 0.138
and 5.01 ± 1.20% vs. 7.12 ± 1.67% i.d./g, P = 0.342,
respectively). Absolute tumor uptake was not informa-
tive on the relationship between tumor localization of
the radioimmunoconjugates and HER2 expression.
Tumor uptake of
111In-DOTA-trastuzumab in MDA-
MB-231, BT-20, MDA-MB-361, or SKOV-3 xenografts
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0.7%, 4.0 ± 0.9%, and 5.4 ± 0.4% i.d./g. Tumor uptake of
64Cu-DOTA-trastuzumab in MDA-MB-231, BT-20,
MDA-MB-361, or SKOV-3 xenografts was 4.4 ± 1.6%,
2.6 ± 1.8%, 5.0 ± 1.2%, and 5.0 ± 3.0% i.d./g. However,
there was a strong direct relationship between T/B
ratios for
111In-DOTA-trastuzumab Fab and tumor
HER2 density (Figure 3a). Moreover, the T/B ratios for
111In-DOTA-trastuzumab Fab were significantly greater
than irrelevant
111In-DOTA-rituximab Fab for MDA-
MB-231, BT-20, and MDA-MB-361 xenografts, demon-
strating specific localization. The T/B ratios for
64Cu-
DOTA-trastuzumab Fab were significantly greater than
64Cu-DOTA-rituximab Fab for MDA-MB-361 tumors
with high HER2 density (P < 0.001), but not for MDA-
MB-231 or BT-20 xenografts with low HER2 expression
(P = 0.0709 and 0.528, respectively; Figure 3b). The
localization of
111In- or
64Cu-DOTA-rituximab Fab in
SK-OV-3 tumors was not determined. No relationship
between the T/B ratios for
64Cu-DOTA-trastuzumab
Fab and HER2 density was established (Figure 3b).
MicroSPECT/CT and microPET/CT imaging
Representative microSPECT and microPET images of
athymic mice with s.c. tumor xenografts with increasing
HER2 density at 24 h p.i. of
111In- or
64Cu-DOTA-tras-
tuzumab Fab, respectively are shown in Figures 4 and 5.
MicroSPECT/CT and microPET/CT images were
displayed as coronal slices with the plane selected to
optimally display the tumor uptake of
111In-DOTA-tras-
tuzumab Fab or
64Cu-DOTA-trastuzumab Fab. MDA-
MB-231 tumors with low HER2 expression (5.4 × 10
4
receptors/cell; Figures 4a and 5a) were least intensely
imaged while SK-OV-3 tumors with high HER2 density
a
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Figure 1 SDS-PAGE and size-exclusion HPLC. (a) SDS-PAGE analysis on a 4% to 20% Tris HCl gradient mini-gel stained with Coomassie
Brilliant Blue of trastuzumab (lane 1), trastuzumab Fab (lane 2), and DOTA-trastuzumab Fab (lane 3) under non-reducing conditions or these
same proteins under reducing conditions (lanes 4 to 6, respectively). Molecular weight markers are shown (lane MW). The positions of 150, 50,
and 25 kDa markers are indicated. Size-exclusion HPLC analyses of (b)
111In-DOTA-trastuzumab Fab (top panel) and (c)
64Cu-DOTA-trastuzumab
Fab (bottom panel) with detection of absorbance at 280 nm or radioactivity.
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6 receptors/cell) were most clearly seen (Figures
4c and 5c) with
111In- or
64Cu-DOTA-trastuzumab. An
intermediate tumor signal was found for MDA-MB-361
xenografts with 5.1 × 10
5 HER2/cell (Figures 4b and
5b). The specificity of tumor localization of
111In- or
64Cu-DOTA-trastuzumab Fab was shown by the lower
accumulation of
111In- or
64Cu-DOTA-rituximab Fab on
images of mice bearing MDA-MB-361 xenografts (Fig-
ures 4d and 5d). There was no difference in the ability
of
111In- or
64Cu-DOTA-trastuzumab Fab to image
small (5 to 10 mm; Figure 6a,c) or larger (10 to 15 mm;
Figure 6b, d) MDA-MB-361 tumors. The kidneys were
most prominent on microSPECT images of
111In-
DOTA-trastuzumab Fab, while microPET with
64Cu-
DOTA-trastuzumab Fab showed high liver and kidney
uptake.
Discussion
Our results revealed that both microSPECT/CT and
microPET/CT with
111In- or
64Cu-DOTA-trastuzumab
Fab fragments were able to image s.c. human tumor
xenografts in mice with low, intermediate, or high HER2
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Figure 2 Direct (saturation) radioligand binding assays. Direct (saturation) radioligand binding to SKBR-3 human breast cancer cells of (a)
111In-DOTA-trastuzumab Fab or (b)
64Cu-DOTA-trastuzumab Fab, in the absence (total binding; TB) or presence (non-specific binding; NSB) of
excess (16 μM) unlabeled trastuzumab IgG. Specific binding (SB) was calculated by subtraction of NSB from TB. Curves were fitted to a 1-site
receptor-binding model using Prism Ver. 4.0 software (GraphPad).
Table 1 Tumor and normal tissue distribution at 24 h
post-injection of
111In- or
64Cu-DOTA-trastuzumab Fab
Percent injected dose/g
a, b, c
Tissue
111In-DOTA-trastuzumab
Fab
64Cu-DOTA-trastuzumab
Fab
Blood 0.42 ± 0.08 1.40 ± 0.16
Heart 0.92 ± 0.06 2.42 ± 0.39
Lungs 0.80 ± 0.14 4.86 ± 0.57
Liver 3.13 ± 0.16 8.52 ± 0.81
Kidneys 62.85 ± 6.45 57.00 ± 7.09
Stomach 0.58 ± 0.05 3.41 ± 0.22
Intestines 0.61 ± 0.06 4.76 ± 0.41
Spleen 2.25 ± 0.13 5.00 ± 0.27
Muscle 0.78 ± 0.31 0.75 ± 0.06
Tumor 4.00 ± 0.91 5.01 ± 1.20
111In- or
64Cu-DOTA-trastuzumab Fab in athymic mice bearing subcutaneous
MDA-MB-361 human breast cancer xenografts.
aValues shown are mean ± SD
(n = 4).
bSignificantly different for
111In- and
64Cu-DOTA-trastuzumab Fab for
blood, heart, lungs, liver, stomach, intestines, and spleen (all P < 0.001).
cNot
significantly different for
111In- and
64Cu-DOTA-trastuzumab Fab for kidneys,
muscle, or tumor (P > 0.05).
Table 2 Tumor/normal tissue (T/NT) ratios at 24 h post-
injection of
111In- or
64Cu-DOTA-trastuzumab Fab
T/NT Ratio
a, b, c
Tissue
111In-DOTA-trastuzumab
Fab
64Cu-DOTA-trastuzumab
Fab
Blood 9.73 ± 2.46 3.56 ± 0.62
Heart 4.31 ± 0.83 2.09 ± 0.56
Lungs 5.06 ± 1.12 1.03 ± 0.19
Liver 1.27 ± 0.26 0.59 ± 0.16
Kidneys 0.06 ± 0.02 0.09 ± 0.02
Stomach 6.99 ± 2.05 1.48 ± 0.37
Intestines 6.61 ± 1.78 1.05 ± 0.22
Spleen 1.79 ± 0.48 1.00 ± 0.20
Muscle 6.12 ± 3.33 6.78 ± 1.90
111In- or
64Cu-DOTA-trastuzumab Fab in athymic mice bearing subcutaneous
MDA-MB-361 human breast cancer xenografts.
aValues shown are mean ± SD
(n = 4).
bSignificantly different for
111In- and
64Cu-DOTA-trastuzumab Fab for
lungs and intestines (both P < 0.001), blood, heart, liver, stomach (all P < 0.01)
and spleen (P < 0.05).
cNot significantly different for
111In- and
64Cu-DOTA-
trastuzumab Fab for kidneys and muscle (P > 0.05).
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Page 6 of 11expression. The range of HER2 expression examined
(5.4 × 10
4 to 1.2 × 10
6 receptors/cell) corresponded to
HER2 scores of 0 to 3+ assessed clinically in BC speci-
mens by IHC staining [9]. There was no apparent
increased ability of microPET/CT with
64Cu-DOTA-
trastuzumab Fab compared to microSPECT/CT with
111In-DOTA-trastuzumab Fab to visualize MDA-MB-
231 tumors with low HER2 density (1.6 × 10
5 receptors/
cell; Figures 4a and 5a). In addition, there was no
increased ability of microPET/CT using
64Cu-DOTA-
trastuzumab Fab to image small (5 to 10 mm diameter)
or larger (10 to 15 mm diameter) MDA-MB-361 tumors
with intermediate HER2 expression (5.1 × 10
5 HER2/
cell; Figure 6). The intensity of the tumor signal was
dependent on HER2 expression with tumors with inter-
mediate (MDA-MB-361) or high (SK-OV-3) HER2 den-
sity most readily imaged by microSPECT/CT (Figure 4)
or microPET/CT (Figure 5). However, a threefold higher
dose of radioactivity was administered for microSPECT/
CT than microPET/CT (70 vs.2 2M B q )a n di m a g e
acquisition times were up to sixfold longer for micro-
SPECT/CT (85 to 20 vs. 20 min, respectively). Thus, the
photon detection efficiency (i.e., intrinsic sensitivity) was
much higher for microPET/CT than microSPECT/CT.
Nonetheless, our results revealed that provided that the
administered dose of radioactivity was sufficient and
image acquisition times were long enough to yield good
counting statistics, microSPECT/CT with
111In-DOTA-
trastuzumab Fab was able to image tumors with the
similar HER2 density and size as microPET/CT with
64Cu-DOTA-trastuzumab. These results agree with
those reported by Cheng et al. who noted that s.c.
HER2-positive SUM190 tumor xenografts were imaged
by either microSPECT or microPET using trastuzumab
conjugated to biotinylated
99 mTc- or
18F-labeled phospho-
diamidate morpholinos (MORFs) through a streptavidin
linker [28]. The doses of
99 mTc or
18F used in their study
were 13 and 0.22 MBq, respectively. Phantom studies
revealed that microPET was 15-fold more sensitive in
terms of photon detection, but the spatial resolution
of microSPECT was superior to that of microPET (1.2 vs.
2.4 mm). The results are also in concordance with those
reported by Wong et al. [29], who showed that s.c. epider-
mal growth factor receptor-positive LS174T human colon
cancer xenografts could be imaged using panitumomab F
(ab’)2 fragments labeled with
111In or
86Y. However, they
compared low resolution planar g-camera imaging with
microPET. In our study, we used similar quality high reso-
lution and high sensitivity small animal imaging technolo-
gies, namely microSPECT/CT (NanoSPECT; Bioscan) and
a b
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Figure 3 Tumor/blood (T/B) ratios. T/B ratios at 24 h p.i. of (a)
111In-DOTA-trastuzumab Fab and
111In-DOTA-rituximab Fab or (b)
64Cu-DOTA-
trastuzumab Fab and
64Cu-DOTA-rituximab Fab, in s.c. human tumor xenografts in athymic mice with increasing HER2 expression. Values shown
are mean ± SD (n = 4). The HER2 density (receptors/cell) was 5.4 × 10
4 (MDA-MB-231), 1.6 × 10
5 (BT-20), 5.1 × 10
5 (MDA-MB-361) and 1.2 × 10
6
(SK-OV-3). Significant differences (P < 0.05) between
111In- or
64Cu-labeled trastuzumab Fab and rituximab Fab are indicated by asterisks. n.d., not
determined.
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Page 7 of 11microPET (Siemens Focus 220) systems for these
comparisons.
T/B ratios were used to compare the tumor localization
of
111In- and
64Cu-DOTA-trastuzumab Fab vs.H E R 2d e n -
sity because we previously found that there are differences
in perfusion between different tumor xenografts which
can affect the uptake of radioimmunoconjugates [9]. Use
of T/B ratios minimizes these effects by normalizing for
blood concentrations which then reveals the relationships
between HER2 density and tumor accumulation. More-
over, the T/B ratios are important for discriminating
tumors that have different HER2 expression on the
images. There was a strong and direct association between
the T/B ratios for
111In-DOTA-trastuzumab and tumor
HER2 density (Figure 3a). In addition, the T/B ratios for
111In-DOTA-trastuzumab Fab were significantly greater
than those of irrelevent control
111In-DOTA-rituximab
Fab for MDA-MB-231, BT-20, and MDA-MB-361 xeno-
grafts, demonstrating specific localization in tumors with
low or intermediate HER2 expression. In contrast, specific
uptake of
64Cu-DOTA-trastuzumab Fab was shown in
MDA-MB-361 tumors with intermediate HER2 density
but not for tumors with lower HER2 expression (Figure
3b). Tumor uptake was not significantly different for
64Cu- and
111In-DOTA-trastuzumab Fab, but blood
radioactivity was threefold lower for
111In-DOTA-trastu-
zumab Fab (Table 1). Thus, T/B ratios were threefold
lower for
64Cu- than
111In-DOTA-trastuzumab (3.6:1 vs.
10:1; Table 2) in mice with MDA-MB-361 tumors. The
increased circulating radioactivity for
64Cu-DOTA-trastu-
zumab Fab may be due to kinetic instability of the
64Cu-
DOTA complex with transchelation of released
64Cu to
copper binding proteins (e.g., albumin, ceruloplasmin, or
superoxide dismutase) [26]. These
64Cu-labeled proteins
may non-specifically localize in tumors, disrupting the
association between T/B ratios and HER2 density, espe-
cially for tumors with low HER2 expression (i.e., MDA-
MB-231 and BT-20).
DOTA forms thermodynamically stable complexes with
copper (Kd =1 0
23 M
-1) but kinetic instability of
64Cu-
DOTA complexes in vivo can lead to loss of radiometal
resulting in high blood radioactivity and liver and spleen
uptake [17]. In addition to the higher levels of blood radio-
activity, we found that the liver and spleen uptake for
64Cu-DOTA-trastuzumab Fab were three- and twofold
greater, respectively, than
111In-DOTA-trastuzumab Fab
(Table 1). In order to improve the kinetic stability of
64Cu
complexes, more thermodynamically stable cross-bridged
(CB-DO2A) or sarcophagine (SarAr) chelators have been
synthesized [30,31]. A comparison of
64Cu complexed to
a b cd
Figure 4 Coronal slice microSPECT/CT images. Images of athymic mice with s.c. human tumor xenografts (solid arrows) with increasing HER2
expression at 24 h p.i. of 70 MBq (10 μg) of
111In-DOTA-trastuzumab [panels (a), (b), (c)] or
111In-DOTA-rituximab Fab [panel (d)]. (a) Mouse with
MDA-MB-231 (left panel) and BT-20 (right panel) xenografts with low HER2 density (5.4 × 10
4 and 1.6 × 10
5 receptors/cell, respectively). (b)
Mouse with MDA-MB-361 xenograft with intermediate HER2 density (5.1 × 10
5 receptors/cell). (c) Mouse with 15 to 18 mm diameter (left flank)
and 5 to 10 mm diameter (right flank) SK-OV-3 xenografts with high HER2 density (1.2 × 10
6 receptors/cell). (d) Mouse with MDA-MB-361
xenograft with intermediate HER2 density (5.1 × 10
5 receptors/cell). Bladder radioactivity in panel (c) is indicated by broken arrow. Image
acquisition time was 85 to 120 min and anaesthesia was induced and maintained by inhalation of 2% isoflurane in oxygen. Images were
adjusted to approximately equal intensity.
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Figure 5 Coronal slice microPET/CT images. Images of athymic mice with s.c. human tumor xenografts (arrows) with increasing HER2
expression at 24 h p.i. of 22 MBq (10 μg)
64Cu-DOTA-trastuzumab [panels (a), (b), (c)] or
64Cu-DOTA-rituximab Fab [panel (d)]. (a) Mouse with
MDA-MB-231 and BT-20 xenografts implanted on the left and right flanks, respectively with low HER2 density (5.4 × 10
4 and 1.6 × 10
5 receptors/
cell, respectively). (b) Mouse with MDA-MB-361 xenograft with intermediate HER2 density (5.1 × 10
5 receptors/cell). (c) Mouse with 15 to 18 mm
diameter (left) and 5 to 10 mm diameter (right) SK-OV-3 xenografts with high HER2 density (1.2 × 10
6 receptors/cell). (d) Mouse with MDA-MB-
361 xenograft with intermediate HER2 density (5.1 × 10
5 receptors/cell). Bladder radioactivity seen in one mouse is indicated by a broken arrow.
Image acquisition time was 20 min and anaesthesia was induced and maintained by inhalation of 2% isoflurane in oxygen. Images were
adjusted to approximately equal intensity.
ab cd
Figure 6 Coronal slice microSPECT/CT [(a) and (b)] or microPET/CT images [(c) and (d)]. Athymic mice with s.c. MDA-MB-361 tumor
xenografts (solid arrows) with intermediate HER2 density (5.1 × 10
5 receptors/cell) at 24 h p.i. of 70 MBq (10 μg) of
111In-DOTA-trastuzumab Fab
or 22 MBq (10 μg) of
64Cu-DOTA-trastuzumab Fab, respectively. (a) and (c) Mouse with 5 to 10 mm diameter tumor. (b) and (d) Mouse with 10
to 15 mm diameter tumor. Image acquisition time was 85 to 120 min for microSPECT and 20 min for microPET. Anaesthesia was induced and
maintained by inhalation of 2% isoflurane in oxygen. Images were adjusted to approximately equal intensity within each modality.
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Page 9 of 11DOTA or CB-DO2A (but not conjugated to mAbs)
showed fourfold lower radioactivity in the blood and two-
fold lower liver accumulation at 24 h p.i. in rats [30]. Voss
et al. noted that ch14.18 mAbs labeled with
64Cu through
the extremely stable SarAr chelator for PET imaging of
neuroblastoma or melanoma xenografts in mice exhibited
low liver uptake (5% to 10% i.d./g) but no comparison
with other chelators was provided [31]. Dearling et al.
recently compared the tumor and normal tissue distribu-
tion of these same
64Cu-labeled ch14.18 mAbs using a
variety of chelators including DOTA and SarAr in mice
bearing M21 melanoma xenografts [17]. Unexpectedly, no
significant differences in tumor or liver uptake were found
for ch14.18 labeled with
64Cu using DOTA or the much
more stable SarAr chelator. They suggested that in addi-
tion to
64Cu-chelator stability, factors such as the net
c h a r g eo nt h ec h e l a t o r sm a yp l a ya ni m p o r t a n tr o l ei n
sequestration of radioactivity by tissues. In our study,
tumor uptake was not significantly different between
111In- and
64Cu-DOTA-trastuzumab Fab in mice with
MDA-MB-361 tumors, despite the apparent instability of
64Cu-DOTA-trastuzumab Fab as evidenced by higher
levels of radioactivity in the blood, liver, and spleen (Table
1). The use of more stable chelators such as CB-DO2A or
SarAr may diminish blood radioactivity and improve the
association between tumor HER2 density and T/B ratios
for
64Cu-labeled trastuzumab Fab. The CB-DO2A and
SarAr chelators are unfortunately not yet commercially
available in a chemically reactive form for conjugation to
mAbs for
64Cu labeling.
Conclusion
Provided that administered doses of radioactivity and
acquisition times were sufficient to yield good counting
statistics, we conclude that either microSPECT/CT with
111In-DOTA-trastuzumab Fab or microPET/CT with
64Cu-DOTA-trastuzumab Fab visualized small (5 to
10 mm diameter) or larger (10 to 15 mm diameter) s.c.
tumor xenografts with low, intermediate, or high HER2
expression in athymic mice. However, due to the higher
levels of circulating radioactivity for
64Cu-DOTA-trastuzu-
mab Fab, no association between HER2 density and T/B
ratios was established. In contrast, there was a strong
direct association between T/B ratios and HER2 density of
these tumors for
111In-DOTA-trastuzumab Fab. Thus,
111In-DOTA-trastuzumab Fab was more specific than
64Cu-DOTA-trastuzumab Fab for imaging HER2-positive
tumors with low HER2 density. The use of more stable
CB-DO2A or SarAr chelators for
64Cu may potentially
diminish blood radioactivity, provide a stronger associa-
tion between T/B ratios and tumor HER2 density, and
improve the specificity of imaging with
64Cu-labeled tras-
tuzumab Fab.
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